Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All

被引：22
作者：
Andre, Nicolas [1 ,2 ,3 ]
Orbach, Daniel [4 ]
Pasquier, Eddy [2 ,3 ]
机构：
[1] Hop Enfant La Timone, AP HM, Pediat Hematol & Oncol Dept, Marseille, France
[2] Aix Marseille Univ, Ctr Rech Cancerol Marseille Inserm U1068, Marseille, France
[3] Metron Global Hlth Initiat, Marseille, France
[4] PSL Univ, Inst Curie, SIREDO Oncol Ctr Care Innovat & Res Children Adol, Paris, France
来源：
TRENDS IN CANCER | 2020年 / 6卷 / 10期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; HIGH-DOSE CHEMOTHERAPY; LARGE-CELL LYMPHOMA; REGULATORY T-CELLS; CHILDREN; THERAPY; CYCLOPHOSPHAMIDE; PHARMACOKINETICS; IMMUNOTHERAPY; ADOLESCENTS;
D O I：
10.1016/j.trecan.2020.05.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Maintenance therapy sometimes relies on the use of metronomic chemotherapy (MC); that is, the continuous administration of low-dose chemotherapy. Maintenance therapy has been successfully used for decades in pediatric patients with acute lymphoblastic leukemia (ALL) and recent results have demonstrated improved outcomes in patients with pediatric high-risk rhabdomyosarcoma (RMS) on maintenance therapy. Here, we review the use of metronomic maintenance therapy in pediatric cancer and discuss its mechanisms of action on the tumor microenvironment and cancer cells. We also discuss its potential use as a chemotherapy alone or in combination with targeted therapies, immunotherapies, or agents for drug repurposing.
引用
收藏
页码：819 / 828
页数：10
相关论文
共 50 条
[21]   Pediatric High-Risk Conditions [J].
Kettler, Alyssa ;
Claudius, Ilene .
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2025, 43 (01) :41-56
[22]   One size doesn't fit all in Ph-like ALL [J].
Post, Sean M. .
BLOOD, 2017, 129 (02) :140-141
[23]   Micafungin in pediatrics: when one size does not fit all [J].
Ashouri, Negar ;
Singh, Jasjit ;
Arrieta, Antonio .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (04) :463-469
[24]   Treating Constipation With Prucalopride: One Size Does Not Fit All [J].
Nurko, Samuel ;
Saps, Miguel .
GASTROENTEROLOGY, 2014, 147 (06) :1214-1216
[25]   Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay [J].
G Dufort ;
S Pisano ;
A Incoronato ;
M Castiglioni ;
M Carracedo ;
C Pagés ;
E Simon ;
S Zuccolo ;
R Barcelona ;
R Mezzano ;
A Tiscornia ;
F Lemos ;
F Morosini ;
M Schelotto ;
H Giordano ;
E Carreto ;
M Bengoechea ;
B Boggia ;
I Rodriguez ;
L Guerrero ;
A Dabezies ;
L Castillo .
Bone Marrow Transplantation, 2012, 47 :663-668
[26]   Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay [J].
Dufort, G. ;
Pisano, S. ;
Incoronato, A. ;
Castiglioni, M. ;
Carracedo, M. ;
Pages, C. ;
Simon, E. ;
Zuccolo, S. ;
Barcelona, R. ;
Mezzano, R. ;
Tiscornia, A. ;
Lemos, F. ;
Morosini, F. ;
Schelotto, M. ;
Giordano, H. ;
Carreto, E. ;
Bengoechea, M. ;
Boggia, B. ;
Rodriguez, I. ;
Guerrero, L. ;
Dabezies, A. ;
Castillo, L. .
BONE MARROW TRANSPLANTATION, 2012, 47 (05) :663-668
[27]   Autologous hematopoietic cell transplantation for high-risk ALL [J].
Linker, C. ;
Damon, L. ;
Martin, T. ;
Blume, K. ;
Forman, S. ;
Snyder, D. ;
Wolf, J. ;
Negrin, R. .
BONE MARROW TRANSPLANTATION, 2011, 46 (03) :460-461
[28]   Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma [J].
Vural, Sema ;
Genc, Dildar Bahar ;
Kebudi, Rejin ;
Dogan, Oner ;
Karaman, Serap .
TURKISH JOURNAL OF PEDIATRICS, 2021, 63 (04) :639-647
[29]   Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma [J].
Mora, Jaume .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) :647-653
[30]   Margin Status Following PartialMastectomy: One Size Does Not Fit All! [J].
Margenthaler, Julie A. ;
Klimberg, V. Suzanne .
ONCOLOGY-NEW YORK, 2011, 25 (10) :899-+
12345